View more on these topics

Shooting from the hip

Threadneedle’s schadenfreude in a recent global healthcare outlook report is a touch too much for the Diary.

It seems the pros-pect of all our elder relatives’ hip replace-ments is seeing the firm rubbing its hands.

The effect of the obesity epidemic on demand for synthetic hips and knees may be good business but the Diary thinks a heading of “hip, hip, hooray” wouldn’t go down well with afflicted investors.

Recommended

Richard Verdin on protection

I and others have written about the possible outcomes of statutory regulation for those selling protection products yet among the many advisers I speak to, I sense that the majority are focused only on the short-term effects of simply meeting the required pre-sale and sale processes in the belief that if they get these right, then everything will be OK.

Brexit & the mid cap buying opportunities

By Mark Martin, Head of UK Equities at Neptune  Amid the market volatility in the lead-up to the Brexit referendum, there are buying opportunities for the prudent investor, explains Mark Martin. Click here for full article Important Information: Investment risks This fund may have a high volatility rating and past performance is not a guide […]

Newsletter

News and expert analysis straight to your inbox

Sign up

Comments

    Leave a comment